| Your Source for the Latest Patent Information |
User Functions Categories- All
- Announcements (5)
- In The News (609)
- OG Notice Links (306)
- Patents of the Day (468)
Archives- December 2007 (18)
- November 2007 (36)
- October 2007 (45)
- September 2007 (36)
- August 2007 (36)
- July 2007 (44)
- June 2007 (36)
- May 2007 (45)
- April 2007 (36)
- March 2007 (36)
- February 2007 (39)
- January 2007 (44)
- more...
Search Syndication Credits- powered by b2evo
- skin cloned from Movable Type
|
GEN-ERIC Patent News
Your Source for the Latest Patent Information
10/03/06
7,117,254 Method of inducing content uploads in a social network  10/03/06
7,116,763 Voice and motion activated telephone  10/03/06
7,114,450 Magazine for receiving electric shock bullets  10/03/06
C.R. Bard Inc., a maker of medical devices used in oncology and urology, on Thursday said it agreed to pay $20 million to settle a lawsuit accusing it of patent infringement. Im a regulatory filing, the Murray Hill, New Jersey-based company said the case involved allegations that it infringed patents for dialysis catheters. A catheter is a thin tube that can be inserted into the body to drain or infuse fluids. Under the settlement, C.R. Bard will acquire a paid-up license under the patents at issue, and obtain an agreement not to be sued over its existing products. It will record a $20 million third-quarter pre-tax charge for the settlement. Posted by GEN-ERIC at 12:12:38 am into the following categories: In The News10/03/06
The DOJ and PTO have given their solid support to Microsoft’s petition for certiorari in its battle over transnational patent infringement. This support makes grant of the petition highly likely. This case, like Eolas and Pellegrini before, questions the scope of Section 271(f) of the Patent Act. That statute allows a U.S. patentee to collect damages for foreign sales of a patented invention based on the export of one or more of its components from the U.S. Recently, the CAFC has expanded the common interpretation of the statute to include the export of software code (AT&T, Eolas) as well as to the export of elements used in a patented method (Union Carbide). In a case that is difficult to square with AT&T or Eolas, the court held that the “component” does not apply to plans or instructions. In this case, Microsoft’s software code was generated in the U.S. and then shipped abroad where copies were then generated and distributed. AT&T claims (and courts have thus far agreed) that sales of those foreign copies infringe the U.S. patent and create liability. Posted by GEN-ERIC at 12:11:35 am into the following categories: In The News10/03/06
A U.S. court on Monday denied a Qualcomm Inc. (QCOM.O) request for a preliminary injunction in a legal dispute with rival chip maker Broadcom Corp. (BRCM.O), Broadcom said. A U.S. district judge in San Diego ruled that Qualcomm was not entitled to the injunction to stop Broadcom's development and sale of third-generation ("3G") cellular chips, Broadcom said. Broadcom said it and Qualcomm are to agree on a set of documents to be quarantined pending the outcome of the case, whose trial is set for October 2007. It said it has not misused any Qualcomm trade secrets. The hearing at the U.S. District Court in San Diego, California relates to a complaint from Qualcomm accusing Broadcom of misuse of trade secrets. Qualcomm sells technology licenses and chips for mobile phones. The companies have traded lawsuits in recent months with cases including patent infringement claims from both sides and anti-competitiveness allegations by Broadcom against Qualcomm. Posted by GEN-ERIC at 12:10:19 am into the following categories: In The News10/03/06
Japan's Central Glass Co. Ltd. said on Friday that it and Abbott Laboratories Inc. of the United States have won a patent lawsuit against Baxter International Inc., related to the anaesthesia drug sevofluran. Central Glass, a major sheet glass maker that also makes drugs including sevofluran, filed a lawsuit last May with the Tokyo District Court saying the content of generic drug produced by United States-based Baxter violated its sevofluran patent. The court ruling could ban Baxter from importing and selling its drug in Japan. Central Glass official Takeo Tanaka said it uses Abbott's sales channels to market sevofluran around the world. Early this year, Baxter started selling its generic drug in Japan and the United States. Posted by GEN-ERIC at 12:09:00 am into the following categories: In The News
|
Calendar| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| << < | > >> | |||||
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 | 31 | |||||
LinksEmployment
USPTO
